Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02153476 · ClinicalTrials.gov registry record · Phase 2
A Safety And Efficacy Study Of Alg-1001 In Human Subjects With Symptomatic Focal Vitreomacular Adhesion
A Phase 2 study of Symptomatic Focal Vitreomacular Adhesion, sponsored by Allegro Ophthalmics.
- Completed
- Registry status
- Phase 2
- Development phase
- 45
- Enrollment target
- 5
- Study locations
NCT02153476: Completed Phase 2 study of Symptomatic Focal Vitreomacular Adhesion, sponsored by Allegro Ophthalmics.
NCT02153476 is a Phase 2 study of Symptomatic Focal Vitreomacular Adhesion that has completed, run by Allegro Ophthalmics. The registered enrollment target is 45 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (66% lower). The trial reports 5 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02153476, a Phase 2 study of Symptomatic Focal Vitreomacular Adhesion, has completed, sponsored by Allegro Ophthalmics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 45 participants
- Enrollment target
- 5
- Study locations
Study Summary
Evaluate the safety and efficacy of ophthalmic intravitreal injection of ALG-1001 in human subjects with symptomatic focal vitreomacular adhesion
Primary Outcome
The primary endpoint of this study is observation of pharmacologic resolution of VMA, with VMA defined as vitreous adhesion to the macula within a 6mm central retinal field surrounded by elevation of the posterior vitreous cortex as seen on OCT.
Conditions Studied
Interventions
- DRUG 2.0mg of ALG-1001
- DRUG Balanced Salt Solution
Study Locations (5)
California
- Retina-Vitreous Associates Medical Group - Beverly Hills
- California Retina Consultants - Santa Barbara
Texas
- Austin Retina Associates - Austin
- Retina Consultants Houston - Houston
Florida
- Center for Retinal and Macular Disease - Winter Haven
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 45 participants |
| Start Date | 2014-02 |
| Est. Completion | 2015-06 |
| Phase | Phase 2 |
What the finished NCT02153476 record still lists
NCT02153476 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 45 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (66% lower).
The record links to 1 condition, with Symptomatic Focal Vitreomacular Adhesion appearing as the primary indexed condition, and to 2 interventions - of which 2.0mg of ALG-1001 is the first listed.
NCT02153476 lists 5 locations in 3 states (California, Texas, Florida).
Frequently Asked Questions
What is clinical trial NCT02153476 about?
NCT02153476 is a clinical study titled "A Safety And Efficacy Study Of Alg-1001 In Human Subjects With Symptomatic Focal Vitreomacular Adhesion". Evaluate the safety and efficacy of ophthalmic intravitreal injection of ALG-1001 in human subjects with symptomatic focal vitreomacular adhesion
What is the current status of trial NCT02153476?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 45 participants. The study started on 2014-02. Estimated completion is 2015-06.
What conditions does trial NCT02153476 study?
This clinical trial studies the following conditions: Symptomatic Focal Vitreomacular Adhesion.
What interventions are being tested in trial NCT02153476?
The interventions under investigation include: 2.0mg of ALG-1001 (DRUG), Balanced Salt Solution (DRUG).
Who is sponsoring clinical trial NCT02153476?
This trial is sponsored by Allegro Ophthalmics, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02153476 being conducted?
This trial has 5 study locations across California, Florida, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02153476's enrollment target sits among peer trials
45 1296th of 2000 higher than 679 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00804154 · 45 participants · Phase 1
Resiniferatoxin to Treat Severe Pain Associated With Advanced Cancer
- NCT01851694 · 45 participants · NA
Beta-cell Response to Incretin Hormones in Cystic Fibrosis
- NCT02896335 · 45 participants · Phase 2
Palbociclib and Pembrolizumab In Central Nervous System Metastases
- NCT03454035 · 45 participants · Phase 1
Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia